Dr. Walter H. Moos

Dr. Walter H. Moos became Managing Director of Pandect Bioventures in 2018 and has been CEO of ShangPharma Innovation since 2017 and an adjunct Professor of Pharmaceutical Chemistry at UCSF since 1992. He was previously President of SRI Biosciences until 2016, after more than a decade at the independent nonprofit SRI International (Stanford Research Institute), which he joined in 2005 as Vice President and Biosciences Division Head. He also managed corporate Information Technology Services at SRI from 2011-2014. Earlier he was Chairman/CEO of MitoKor (Migenix) and a Vice President at Chiron (Novartis) and Warner-Lambert/Parke-Davis (Pfizer).

Moos and his teams have made significant contributions to all R&D phases, from early-stage research on therapeutics and diagnostics to marketed pharmaceutical products. They have advanced many drugs and biologics from bench to bedside, supported by Alta Partners, the Gates Foundation, the National Institutes of Health (NIH), Pfizer, and many others. Moos has served on about 20 business and scientific boards, not-for-profit and for-profit, including Aprinoia Therapeutics, Axiom Biotechnologies (Sequenom), the Biotechnology Industry Organization (BIO), Circle Pharma, the Critical Path Institute, Global Blood Therapeutics, Keystone Symposia, Mimotopes (Thermo Fisher), Oncologic (Aduro), Onyx (Amgen), Rigel Pharma, and Valitor.

He has advised companies on several continents and served as a committee member for academic, government, and investor groups, including the Univ. of Michigan, the U.S. National Academy of Sciences, and Red Abbey Venture Partners. He has co-founded several scientific journals, co-authored or co-edited 6 books, and has over 170 patents and publications. Moos has held faculty positions at several major universities and received Ph.D. and A.B. degrees in chemistry from U.C. Berkeley and Harvard Univ., respectively.